Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.

Jichao HeRonan P McLaughlinVera van der NoordJohn A FoekensJohn W M MartensGerard van WestenYinghui ZhangBob van de Water

Published in: Breast cancer research and treatment (2019)

mTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.

Keyphrases

induced apoptosis
cell proliferation
cell cycle arrest
oxidative stress
cell death
signaling pathway
cancer therapy
risk assessment
pi k akt
tyrosine kinase
protein kinase
climate change
drug delivery
replacement therapy